Over the past several weeks, our portfolio companies have launched new products, welcomed high-profile experts to their boards of directors, opened new global headquarters, and more. As we near the end of the year, we are excited to see not only this continued momentum within the portfolio but the growth of the Anzu team as well.
Here is a quick preview of the highlights from October:
GelSight launched the latest version of its GelSight Mobile™ probe, the Series 2
Liquid Instruments introduced Multi-instrument Mode and Moku Cloud Compile, two advanced new features designed to serve the rapidly evolving test needs of quantum computing, aerospace, semiconductor, Lidar, and automotive segments
BioFlyte welcomed former U.S. Ambassador and National Security Advisor John Bolton to its Board of Directors
6K was selected as the Manufacturer of the Year for Massachusetts' 14th Essex District and appointed a new Chief Financial Officer with IPO experience
BioSkryb moved into its new global headquarters in Durham, N.C.
Earlier this month, GelSight introduced the latest version of its GelSight Mobile™ probe, the Series 2. This new generation of GelSight’s mobile device offers a sleek form-factor that is one-third lighter and less than half the volume of its predecessor, allowing it to scan surfaces in tighter spaces while maintaining accuracy, speed, and field of view.
The Series 2 product addresses needs in new market verticals and creates new use cases as customers experience its game-changing performance first-hand. After bringing on new CEO, Youssef Benmokhtar, in June 2021, GelSight has set its sights on industries that can benefit from fast, accurate, micron-level measurements on a wide variety of surfaces, such as the additive manufacturing and energy sectors. The company will also continue to grow its core business in automotive, aerospace, and forensics.
Earlier this month, Liquid Instruments announced Multi-instrument Mode and Moku Cloud Compile, two advanced new features designed to serve the rapidly evolving test needs of quantum computing, aerospace, semiconductor, Lidar, and automotive segments.
Multi-instrument Mode is a new paradigm in test systems that allows multiple instruments to be dynamically combined on a single FPGA (Field Programmable Gate Array) chip. For the first time, researchers and engineers have the ability to configure multiple test instruments to run simultaneously on a standalone piece of hardware, with the added ability to implement their own custom code directly onto the FPGA.
Moku Cloud Compile, a subscription service that allows users to design and deploy custom signal processing algorithms to Moku:Pro’s FPGA. The cloud-based tool uses industry-standard hardware description language and provides a simple path from code to deployment. Moku Cloud Compile is fully compatible with Multi-instrument Mode, delivering a complete solution to make unique, custom-built test suites optimized for specific applications and requirements.
BioFlyte Appoints Former U.S. Ambassador and National Security Advisor John Bolton to Board of Directors
BioFlyte recently announced that former U.S. Ambassador and National Security Advisor John Bolton has joined its Board of Directors. As a board member, Ambassador Bolton will help drive awareness for the company and its bio-threat detection technology within the global security market.
Ambassador Bolton most recently served as the National Security Advisor from 2018 to 2019. In 2005, he was nominated to the post of United States Ambassador to the United Nations by President George W. Bush and held that position until the end of 2006. He served as a United States Assistant Attorney General for President Ronald Reagan from 1985 to 1989. Ambassador Bolton then served in the State Department as Assistant Secretary of State for International Organization Affairs from 1989 to 1993, and Under Secretary of State for Arms Control and International Security Affairs from 2001 to 2005.
6K announced that it had been awarded the Manufacturer of the Year for Massachusetts’ 14th Essex district.
6K was nominated by State Representative Christina Minicucci (D-North Andover) and was being honored by the Commonwealth’s Legislative Manufacturing Caucus at Polar Park in Worcester, MA earlier in October. The Caucus, formed in 2014, focuses on training for manufacturing employees, encouraging innovation by helping start-ups access resources, and expanding apprenticeship opportunities in key manufacturing sectors.
The company also announced the appointment of Gary Hall as Chief Financial Officer. He joins 6K with over 20 years of experience leading finance and operational teams at high-growth, technology companies and helping these companies generate significant shareholder value through public and private offerings. Hall will oversee all financial aspects of the company, including financial planning and analysis, financial reporting, accounting and control, tax, and treasury.
Prior to joining 6K, Hall was the Chief Financial Officer of Casa Systems, Inc., a provider of ultra-broadband solutions for mobile, cable, fixed and converged service providers, and helped lead the company through significant growth, culminating in an Initial Public Offering in 2017.
BioSkryb Completes Move into New Global Headquarters in Durham, N.C.
Earlier this month, BioSkryb announced the relocation and expansion of its corporate headquarters and research center in Durham, N.C. to advance the growth and operations of the company. BioSkryb develops single-cell whole genome amplification tools to study genomic heterogeneity and enable the development of new diagnostics for insights into human disease at the cellular level.
The 19,500-square-foot headquarters and innovation space, located in Durham, provides a modern workspace designed for collaboration and company growth. The innovation space includes all new equipment and facilities to support BioSkryb’s new product R&D, in-house testing services, product manufacturing and packaging, and quality control. BioSkryb plans to double its current workforce by the end of next year to a total of 50 highly skilled professionals, including genetic researchers, chemists, software engineers and developers, program managers, and quality control personnel.
Excision BioTherapeutics Expands Management Team with Three Key Appointments
Excision BioTherapeutics announced the expansion of its management team with the appointments of:
Sara Turken, J.D., as General Counsel
Manish Anand, M.Sc., as Senior Vice President, Regulatory Affairs
Robert Gunning, CPA, CGMA, as VP, Controller
Sara Turken, J.D., General Counsel
Sara Turken has spent the last decade working in the healthcare and life sciences industry. She joins Excision from Rocket Pharmaceuticals, Inc., where she was Head of Legal, Compliance Officer & Corporate Secretary, and led all corporate legal affairs including licensing, financing, intellectual property, contracting, litigation, employment, and real estate. Ms. Turken earned her J.D. from Harvard Law School and a B.S. in Industrial and Labor Relations from Cornell University.
Manish Anand is a biopharmaceutical executive with extensive experience managing the regulatory aspects of drug development programs for a wide range of therapeutic modalities including gene therapy, cell therapy, biomolecules, and small molecules. Most recently, Mr. Anand served as Vice President, Regulatory Affairs at Asklepios Biopharmaceuticals, Inc., where he was responsible for multiple gene therapy programs in central nervous system, cardiovascular and metabolic diseases. He earned his B.S. in Chemistry at Lafayette College and his M.S. in Biotechnology at Johns Hopkins University.
Robert Gunning, CPA, CGMA, VP, Controller
Robert Gunning is an experienced accounting and finance professional with more than twenty years of experience working with public and private companies. Prior to joining Excision, Mr. Gunning was the Chief Financial Officer and Head of Finance Transformation at Advanced Accelerator Applications USA, Inc. (a Novartis AG subsidiary), where he executed financial strategies to support project launches and sales growth of LUTATHERA® and NETSPOT®. Mr. Gunning is a Certified Public Accountant in the State of New York and holds a BBA in Public Accounting from Pace University.
Danny Donegan joins Anzu Partners as a Director of Accounting based in Tampa, Florida.
Danny has over 20 years of progressive finance and accounting experience in both public and private sector accounting. After serving in an Army LRS unit on both a Team and in Operations, Danny joined CohnReznick as an Auditor focused on LIHTC Projects.
Danny holds a BBA in Accountancy from Georgia State University and a MAFM (Accounting and Financial Management) from Keller Graduate School.
CAREER OPPORTUNITIES
Anzu Partners and our portfolio companies are hiring!
Browse the open roles here and learn more about joining our amazing teams.
The information contained in this newsletter is being provided by Anzu Partners for informational purposes only. The information was obtained from various sources, but Anzu Partners cannot assure its accuracy. This is neither an offer to sell nor a solicitation for an offer to buy an interest in any fund managed by Anzu Partners. Any such offer or solicitation will only be made to qualified potential investors pursuant to a private placement memorandum. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.
You are receiving this email because you requested to be added to Anzu Partners' monthly newsletter distribution list.
